We investigated 19 patients affected by chronic peripheral neurological disorders treated with therapeutic plasma exchange (TPE) to verify the efficacy of the therapeutic protocol used in these diseases.
Every patient was clinically considered after 5 TPE. Those who showed an improvement started chemotherapy and continued TPE at the rate of 2 procedures/week for 2 weeks, then 1 procedure/week for 1 month and finally 1 procedure every 2 weeks for 2 months. Intravenous immunoglobulins (IVIg) were infused at the end of apheretic treatment in one of the patients affected by neurological disorders due to monoclonal gammopathy undetermined significance. HCV-positive patients with cryoglobulins were treated with α-interferon (α-IFN) for 6 months before TPE. Eleven patients (58%) had a symptomatic improvement, 2 (1.5%) stopped TPE treatment owing to side effects and 6 (31.5%) did not respond to apheretic therapy.
In order to improve the advantages of TPE we suggest using IVIg at the end of apheretic therapy, while in HCV-positive patients, at least one year of α-IFN therapy is required before initiating TPE.
HahnA.F., BoltonC.F., PillayN.. Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.Brain1996; 119: 1055–66.
5.
GorsonK.C., AllamG., RopperA.H.Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.Neurology1997; 48: 321–8.
6.
KellyJ.J., KyleR.A., O'BrienP.C.. Prevalence of monoclonal protein in peripheral neuropathy.Neurology1981; 31: 1480–3.
7.
KyleR.A.“Benign” monoclonal gammopathy. A misnomer?.JAMA1984; 251: 1849–54.
BarohnR.J., KisselJ.T., WarmoltsJ.R., MendellJ.R.Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria.Arch Neurol1989; 46: 878–84.
10.
GosselinS., KyleR.A., DyckP.J.Neuropathy associated with monoclonal gammopathies of undetermined significance.Ann Neurol1991; 30: 54–61.
11.
DyckP.J., LowP.A., WindebankA.J.. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.N Engl J Med1991; 325: 1482–6.
12.
HaflerD.A., JohnsonD., KellyJ.J.. Monoclonal gammopathy and neuropathy: myelin-associated glycoprotein reactivity and clinical characteristics.Neurology1986; 36: 75–8.
13.
Nobile-OrazioE., BarbieriS., BaldiniL.. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies.Acta Neurol Scand1992; 85: 383–90.
14.
NardelliE., BassiA., MazziG., AnziniP., RizzutoN.Systemic passive transfer studies using IgM monoclonal antibodies to sulfatide.J Neuroimmunol1995; 63: 29–37
15.
CornblathD.R., AsburyA.K., AlbersJ.W.. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).Neurology1991; 41: 617–8.
16.
MonacoS., BonettiB., FerrariS.. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy.N Engl J Med1990; 322: 649–52.
17.
BoschE.P., SmithB.E.Peripheral neuropathies associated with monclonal proteins.Med Clin North Am1993; 77(1): 125–39.
18.
KellyJ.J., KyleR.A., MilesJ.M.. Osteosclerotic myeloma and peripheral neuropathy.Neurology1983; 33: 202–10.
19.
DustonMa, SkinnerM., AndersonJ.. Peripheral neuropathy as an early marker of AL amyloidosis.Arch Intern Med1989; 149: 358–60.
PikettyC., MouthonL., KazatchkineM.D.Immunomodulatory effects of plasma exchange and intravenous immunoglobulin (IVIg) in autoimmune and systemic inflammatory diseases. In: RossiU., BusselA., ValbonesiM., eds. Therapeutic Haemapheresis.Milano: SIMTI1995: 127–42.
24.
BlumeG., PestronkA., GoodnoughL.T.Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IVcyclophosphamide.Neurology1995; 45: 1577–80.
25.
MazziG., ZuccoM., AnziniP.. Gammapatia monoclonale di incerto significato con neuropatia cronica da anticorpi anti-solfatidi: ruolo del plasma-exchange.La Trasfusione del Sangue1995; 40(4): 247–51
26.
OksenhedlerE., ChevretS., LegerJ.M.. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy.J Neurol Neurosurg Psychiatry1995; 59: 243–7.
27.
FrankelA.H., SingerD.R.J., WinearslsC.G.. Type essential mixed cryoglobulinemia: presentation, treatment and outcome in 13 patients.Q J Med1992; 298: 101–24.
28.
MazzaroC., PozzatoG., MorettiM.. Long term effects of alpha-interferon therapy for type II mixed cryoglobulinemia.Haematologica1994; 79: 342–9
FerriC., GremignaiG., BombardieriS.. Plasma exchange in mixed cryoglobulinemia. Effects on renal, liver and neurologic involvement.La Ricerca Clin Lab1986; 16: 403–11.
31.
KhellaS.L., FrostS., HermannG.A.. Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: case report and literature review.Neurology1995; 45: 407–11
32.
GhiniM., MasciaM.T., GentiliniM., MussiniC.Treatment of cryoglobulinemic neuropathy with alfa-interferon.Neurology1996; 46, 2: 588–9
33.
CasatoM., LaganàB., AntonelliG., DianzaniF., BonomoL.Long term results of therapy with intereferon-alfa for type II essential mixed cryoglobulinemia.Blood1991; 78: 12: 3142–7
34.
ZuccoM., PassadoreP., PomesA.. Neuropatia periferica secondaria a crioglobulinemia mista HCV correlata: valutazione degli effetti a lungo termine della terapia con interferone alfa.Convegno Nazionale HCV e Patologie correlate. Modena 1996: 128 (abstract)
